Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pacira BioSciences (PCRX)

Pacira cuts 71 jobs in San Diego, retires 45-liter EXPAREL manufacturing suite

Mixed Impact 3 of 5 restructuring Written later

Pacira BioSciences said on July 9, 2025, it reduced its workforce by 71 employees, about 8% of its total, at its San Diego Science Center Campus after decommissioning its 45-liter EXPAREL manufacturing suite. The company expects pre-tax charges of $2.4 million to $2.8 million in the third quarter of 2025, plus $5.4 million in accelerated depreciation. It estimates the move will cut annual operating expenses by about $13 million.

Key points

  • Reduction in force of 71 employees, about 8% of total workforce, at the San Diego Science Center Campus, instituted July 9, 2025
  • Company is decommissioning its 45-liter EXPAREL batch manufacturing suite, citing its 200+ liter suites in San Diego and Swindon, UK
  • Expected pre-tax charges of $2.4 million to $2.8 million in Q3 2025, all cash based, plus $5.4 million in accelerated depreciation
  • Estimated annual reduction in operating expenses of approximately $13 million, before implementation costs

The filing

CompanyPacira BioSciences (PCRX)
Form8-K, current report
Filed with the SECJul 10, 2025, 7:35 AM ET
Accession number0001396814-25-000093

Items reported: 2.05 Exit / Restructuring Costs7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 10, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.